Novel injectable and wet bonding bone adhesive: physicochemical characterization and biocompatibility evaluation Authors: Guibin Huang, Bingqing Li, Yining Liu, Xiwen Zhang, Hongzhi Zhou, Jian Wang, Peng Yu Published: 2026 ABSTRACT AbstractBackgroundBone defect repair is the common clinical dilemmas in surgery, whereas conventional repair materials are limited by poor wet bonding performance, inadequate biocompatibility or the need for secondary surgical removal. To address the above clinical challenges and material defects, this study developed a novel injectable bone adhesive suitable for wet conditions.MethodsA novel injectable wet-bonding bone adhesive (Bone Glue) was fabricated with bioactive glass, tetracalcium phosphate (TTCP), polyglycolic acid (PGA) fibers, phosphoserine (PS) and phosphate solution as raw materials. Its physicochemical properties were characterized, and in vitro cytotoxicity on L-929 cells was assessed by Methyl thiazolyl tetrazolium (MTT) assay; 12-week subchronic systemic toxicity test in SD rats was performed to evaluate in vivo biosafety.ResultsThe Bone glue was injectable. Curing triggered structural cross-linking of Bone Glue, with its adhesive strength to titanium increasing from 0.91 ± 0.14 MPa (initial curing) to 1.26 ± 0.09 MPa (complete curing, P < 0.05). The extract maintained a near-physiological pH (7.30–7.35) for 72 h, and all concentrations exhibited > 70% L-929 cell viability. In vivo, no abnormal symptoms, pathological lesions or significant body weight differences were observed in the Bone Glue group, with minor hematological/biochemical variations within normal ranges.ConclusionsBone glue possesses favorable physicochemical properties and excellent in vitro/in vivo biocompatibility, which makes it a promising biomaterial for dental implant fixation and bone defect repair in minimally invasive clinical applications.Keywords: Bone adhesive, Biocompatibility, Dental implant, Bone repair, Adhesive strength Background Bone defects and complex fractures caused by trauma, infection, tumors, or congenital abnormalities are increasingly common in clinical practice, imposing a heavy burden on patients and society [1]. Minimally invasive surgery has become a mainstream development direction in modern orthopedics due to its advantages of reducing intraoperative trauma, postoperative pain, hospital stay, and complication rates. However, the minimally invasive surgery puts forward higher requirements for bone repair materials, which are expected to have injectability, precise filling ability for irregular defects, and stable adhesion performance under wet physiological conditions (such as blood infiltration), while meeting the core demands of biocompatibility, osteogenic activity, and degradability. Currently, the clinically used bone repair materials are mainly limited to polymethylmethacrylate (PMMA) bone cement, calcium phosphate bone cement (CPC), and metal internal fixation devices (plates, nails, screws). PMMA bone cement, as the first injectable material approved by the FDA for minimally invasive surgery, has excellent mechanical properties but suffers from inherent drawbacks such as biological inertness, non-degradability, monomer toxicity, and severe polymerization exotherm (up to 80 ~ 120 ℃), which can cause thermal damage to surrounding tissues and stress shielding effects, leading to complications such as poor bone-cement interface integration and secondary fractures [2–4]. Although CPC has good biocompatibility and bone conductivity due to its similarity to the inorganic components of natural bone, it has limitations such as poor cohesion, slow degradation rate, and insufficient mechanical strength, which easily result in inadequate intraoperative filling and poor anti-washout performance [5, 6]. Metal internal fixation devices, on the other hand, are difficult to fix small fragments of comminuted fractures, and their non-degradable nature requires a second surgical intervention for removal after bone healing, which increases the patient’s pain and the risk of infection. Bone adhesives, as an alternative to traditional bone repair materials, have attracted extensive attention in recent years due to their ability to achieve rapid bonding of bone fragments, precise filling of irregular defects, and avoidance of secondary surgery [7]. An ideal bone adhesive should meet multiple performance requirements: strong adhesion strength under wet physiological conditions, rapid in-situ curing, good biocompatibility, appropriate degradability that matches the rate of new bone growth, and excellent osteogenic activity. However, the existing bone adhesives still have obvious limitations, such as weak wet adhesion ability, insufficient mechanical properties, inappropriate degradation rate, or lack of osteogenic activity, which hinder their clinical translation and application. To address the above clinical challenges and material defects, this study developed a novel injectable bone adhesive suitable for wet conditions. The bone adhesive is composed of organic-inorganic composite components: the solid phase includes bioactive glass, tetracalcium phosphate (TTCP), polyglycolic acid fibers (PGA) and phosphoserine (PS), while the liquid phase is a phosphate solution. Bioactive glass is widely used in bone repair materials due to its excellent bone conductivity and osteogenic induction ability [8, 9]. TTCP, as a common calcium phosphate component, can participate in the mineralization process of bone tissue and promote new bone formation [10]. PGA fibers can enhance the mechanical strength and toughness of the adhesive at the early stage, reducing its collapsibility [11]. PS, as a bioactive molecule, can enhance the wet adhesion performance and biocompatibility of the material through coordination and ionic interactions [12]. The combination of these components is expected to synergistically improve the comprehensive performance of the bone adhesive. This study aims to systematically evaluate the physicochemical properties and biosafety of the developed wet-adhesive injectable bone adhesive, which is hypothesized to stably adhere under wet conditions for minimally invasive applications (e.g., comminuted bone bonding, bone defect filling, oral and craniomaxillofacial reconstruction) with good osteogenic induction, biocompatibility, and in vivo gradient degradation to induce autologous bone. Compared with traditional materials, it avoids secondary surgery and shortens operation time. Future bone adhesives will focus on adjustable degradation and multi-functional integration (e.g., drug loading, antibacterial, pro-angiogenic), and this study lays a foundation for their clinical translation, with subsequent sections providing experimental data on the adhesive’s key properties. Materials and methods Materials Minimum Essential Medium (MEM), penicillin-streptomycin solution, Trypsin-EDTA (0.25%) and phosphate-buffered saline (PBS) were acquired from Gibco (Grand Island, USA). Fetal bovine serum (FBS) was purchased from Procell (Wuhan, China). Methyl thiazolyl tetrazolium (MTT) was purchased from Amresco (Solon, Ohio, USA). Organic solvents and other compounds were all obtained from Beijing Chemical Reagents Company (Beijing, China). Bone adhesive Mineral-organic bone adhesive Bone Glue was provided by the Suzhou Jiuxin Medical Technology Co., LTD (Suzhou, China) sterilized by gamma irradiation (25–40 kGy). The main components of the powdered material were bioactive glass, TTCP, PGA fiber, and PS. It was mixed with a sterile phosphate solution in a powder to liquid ratio of 3.3 wt/vol. Characterization of bone glue Scanning electron microscopy (SEM) The surface morphology and microstructure of the Bone Glue after curing was characterized by SEM (EPH117, Axia, Thermo Scientific, USA). The vacuum-dried Bone Glue was sputter coated with a thin layer of gold for scanning with SEM at 5 kV. Fourier transform infrared spectroscopy (FTIR) Bone Glue samples before and after curing were dried, ground to a fine powder with potassium bromide, and pressed into pieces using a mold. FTIR spectra were collected on a Nicolet iS10 spectrometer (Thermo Scientific, USA) with wavenumbers ranging from 4000 to 600 cm− 1. Injection property The injectability of Bone Glue was analyzed by electromechanical universal testing machine (UTM4204X, SHENZHEN SUNS TECHNOLOGY STOCK CO., LTD, China). The Bone Glue was prepared by manually mixing and then filled in the 1 mL syringe for injectability evaluation. The extrusion force of the Bone Glue paste extrusion was determined by extrusion at a constant speed (60 mm/min). Lap shear adhesion test of titanium substrates The adhesive strength in wet conditions of the Bone Glue adhesive was investigated by shear-lap tests on two titanium sheets (100 mm long × 25 mm wide × 1.6 mm thick) with standard geometry and size according to ISO 4587. The Bone Glue adhesive was evenly coated on one end of the titanium plate, and then another titanium plate was placed on it, and gently pressed for 1 min to ensure that the overlap area of the two titanium plates was 25 mm × 10 mm (Fig. 4A). Then the samples were immersed in PBS at 37 ℃ for curing for 10–18 h, and the bonding strength of the Bone Glue adhesive to the titanium plate was tested by universal testing machine (3365, Instron, USA). The sensor was 5 kN, and the tensile rate was 5 mm/min. The bonding strength was calculated as the maximum load force divided by the bonding overlap area. Bonding strength of the Bone Glue. A Schematics of the lap-shear adhesion test. B The adhesion strength of Bone Glue after immersion in PBS solution for 10 min and 18 h. * P<0.05 PH value of bone glue extract The Bone Glue samples after curing were placed in Tris(hydroxymethyl)aminomethane (TRIS) buffer solution (pH = 7.3 + 0.1) at 37 ℃, and loaded on a shaker with a speed of 200 rpm/min for 0 h, 24 h, 48 h and 72 h, respectively. The pH values of the extract after 0 h, 24 h, 48 h, and 72 h of immersion were measured using a pH meter (PHBJ-260 F, INESA, Shanghai, China) according to GB/T 9724. Cytotoxicity test in vitro Cured Bone Glue (10 g) was immersed in 3 mL of MEM and incubated at 37 °C with shaking at 40 rpm for 72 h. The obtained extracts were serially diluted to 100%, 75%, 50% and 25% (v/v) for L-929 cell (National Collection of Authenticated Cell Cultures, Shanghai, China) treatment, with MEM, high-density polyethylene film (3 cm²/mL) and powdered latex gloves (6 cm²/mL) serving as blank, negative and positive controls, respectively. According to ISO 10993-5: 2009 [13], the cytotoxicity of Bone Glue was assessed via MTT assay: L-929 cells (1 × 10⁵ cells per well) were seeded in 96-well plates, serum-starved for 24 h for synchronization, and then cultured in each group’s medium at 37 °C for another 24 h. The cells were subsequently incubated with 10% MTT reagent in medium at 37 °C for 4 h, and the absorbance of five replicate wells was measured at 490 nm using a microplate reader (ELx800, BioTek, USA). Cell viability (%) = (ODsample/ODblank control) × 100%. Subchronic systemic toxicity test in vivo Ethics approval All animal experiments complied with the Guide for the Care and Use of Laboratory Animals and were approved by the Animal Ethics Committee of Xiamen Medical College (Approval No.20251023002). Animals Six-week-old SD rats (20 males/20 females) were purchased from Charles River (Zhejiang, China). Housed in SPF conditions, they received standard chow/water ad libitum with 1-week acclimation. Experimental grouping and treatment Forty rats were randomized into 2 groups (n = 20/group, 10 males/10 females): (1) Control: high-density polyethylene (0.6 g/animal); (2) Bone Glue: cured Bone Glue (0.6 g/animal). The subchronic observation period was 12 weeks according to ISO 10993-11: 2017 [14]. Rats were anesthetized with pentobarbital sodium (50 mg/kg, i.p.). Dorsal fur was shaved, disinfected, and a 2 cm incision made. A subcutaneous pouch was dissected, and the implant placed ≥ 10 mm from the incision. The incision was sutured, re-disinfected, and checked daily postoperatively. Observation indicators and detection methods General clinical observation Daily observations included activity, appetite, secretions, and mortality. Body weight was weekly measured to assess growth. Sample collection At week 12, rats were fasted overnight, anesthetized, and abdominal aorta blood collected (for hematology and biochemistry). Rats were sacrificed by an excessive anesthesia with pentobarbital sodium, necropsied, and organs excised, weighed (organ coefficient calculated), and fixed in 10% formalin. Hematological and biochemical analysis At the end of the experiment, blood samples of rats were collected for hematology, coagulation and serum biochemistry analyses. The indexes were detected by automatic blood cell analyzer and biochemical analyzer (BC-5180CRP and BS-370E, Mindray, Shenzhen). The detailed indexes are shown in Table 1. Table 1Summary of hematological parameters and biochemical indexesBlood testIndexesBlood routine- Total white blood cell (WBC)- Differential white blood cell count (N, L, M, B) a- Percentage of differential white blood cells (%)- Red blood cell (RBC)- Hemoglobin (HGB)- Hematocrit (HCT)- Platelet (PLT)Blood coagulation- Prothrombin time (PT)- Activated partial thromboplastin time (APTT)Blood biochemistry- Total bilirubin (TBIL)- Total protein (TP)- Albumin (ALB)- Globulin (GLOB)- Albumin/globulin (A/G)- Alanine aminotransferase (ALT)- Aspartate aminotransferase (AST)- Alkaline phosphatase (ALP)- Blood urea nitrogen (BUN)- Creatinine (CREA)- Glucose (GLU)- Glutamyl transpeptidase (GGT)- Total cholesterol (TC)- Triglyceride (TG)- Kalium (K)- Natrium (Na)- Chlorine (Cl)- Calcium (Ca)- Phosphorus (P)a N means NEUT (neutrophil). L means LYMPH (lymphocyte). M means MONO (monocytes). B means BASO (basophile). Summary of hematological parameters and biochemical indexes a N means NEUT (neutrophil). L means LYMPH (lymphocyte). M means MONO (monocytes). B means BASO (basophile). Organ weight and organ coefficient Following euthanasia, major organs including the brain, cardiac, liver, spleen, kidneys, thymus, testes and epididymides (males), uterus and oophorons (females) were dissected and harvested. The absolute wet weights of these organs were measured, and the organ-to-body weight indices (organ weight/body weight × 1000‰) were calculated accordingly. Histopathological examination The histomorphology of brain, cardiac, liver, spleen, lung, kidney, testis and oophoron were observed. Tissues were dehydrated, embedded, sectioned (5 μm), hematoxylin-eosin (H&E) stained, and observed via microscope (Axio Imager, Zeiss, Germany). Statistical analysis Data were expressed as mean ± standard deviations (SD). Statistical analysis used SPSS 25.0 or GraphPad Prism 10.1.1. Independent sample t-test and one-way ANOVA with Bonferroni’s test was applied. P < 0.05 was significant. Results Microstructure SEM images (Fig. 1) showed that the Bone Glue was cured into a whole block, containing some microporous structure (<50 μm), and PGA fibers were scattered in it. Surface morphology of Bone Glue under scanning electron microscope (SEM). A shows the field of view at a magnification of 200 times, and bar represents 200 μm. B shows the field of view at a magnification of 1000 times, and bar represents 4 μm FTIR spectrogram FTIR analysis (Fig. 2) demonstrated that spectral differences between the Bone Glue before and after curing were mainly distributed in the fingerprint region. Strong absorptions at 1000–1500 cm⁻¹ and 1500–1750 cm⁻¹ were assigned to C–O and C = C stretching vibrations, respectively. After curing, both absorptions decreased significantly, with the most obvious attenuation at 1000–1500 cm⁻¹, indicating efficient removal of C–O-containing groups. Fourier-transform infrared spectroscopy (FTIR) spectra of Bone Glue. B is the enlargement of the area to the right of (A). The black line corresponds to the Bone Glue before curing. The red line to the Bone Glue after curing Injection property The Bone Glue had excellent injectability as shown in Fig. 3A. The injection force increased with the increase of displacement, but the peak value was only 25 N (Fig. 3B.), indicating that the material could be easily injected and had good clinical operability. Injectability of Bone Glue. A Injectable bone adhesive Bone Glue diagram. B The injection curve of Bone Glue Adhesion strength The adhesion strength of Bone Glue was evaluated via a titanium plate-bone adhesive-titanium plate lap shear model (Fig. 4A). Results (Fig. 4B) revealed adhesion strength of Bone Glue were 0.91 ± 0.14 MPa at initial curing and 1.26 ± 0.09 MPa at complete curing. Statistical analysis confirmed a significant difference (P < 0.05), indicating enhanced adhesive performance with extended curing time. PH value of bone glue extract The pH dynamics of Bone Glue extract over 0–72 h are shown in Fig. 5. During 0–24 h, the initial pH (7.35 ± 0.02) decreased rapidly (7.31 ± 0.01), but only by 0.03 units reduction. During 24–72 h, the pH value tended to stabilize at 7.30 ± 0.01. The pH values of TRIS after the Bone Glue immersion for 72 h Cytotoxicity test in vitro The MTT assay results (Fig. 6) demonstrated that the cell viability levels of the Bone Glue extract at concentrations of 100%, 75%, 50%, and 25% all exceeded 70%, indicating that the Bone Glue exhibited no cytotoxicity and possessed favorable biocompatibility. The viability of L-929 cells with different concentrations of Bone Glue extract Subchronic systemic toxicity test in vivo General clinical observation During the experimental period, no mortality or moribundity was observed in any group of animals, and no abnormal clinical manifestations were noted. No test article‑related toxic symptoms (e.g., convulsions, ataxia, vomiting, diarrhea, etc.) were detected. Hematological and biochemical analysis In males (Tables 2 and 3), no significant differences were observed between the Bone Glue and control groups in most hematological (WBC, NEUT, LYMPH, MONO, BASO, NEUT%, LYMPH%, MONO%, BASO%, RBC, HGB, HCT), coagulation (PT, APTT) and biochemical parameters (TBIL, TP, ALB, GLOB, A/G, ALT, ALP, BUN, CREA, GLU, GGT, TC, TG, K) (P > 0.05), while significant differences were found in hematological parameters (EO, EO%, PLT) and biochemical parameters (AST, Na, Cl, Ca, P) (P < 0.05). In females (Tables 4 and 5), no significant differences were detected in the majority of hematological (WBC, LYMPH, MONO, EO, BASO, LYMPH%, MONO%, EO%, BASO%, RBC, HGB, HCT, PLT), coagulation (PT, APTT) and biochemical parameters (TBIL, TP, ALB, GLOB, A/G, ALT, AST, ALP, BUN, CREA, GLU, GGT, TC, TG, K, Na, Cl) (P > 0.05), whereas significant differences were noted in hematological parameters (NEUT, NEUT%) and biochemical parameters (Ca, P) (P < 0.05). No Bone Glue related abnormalities in erythrocytes, leukocytes, platelets or hematopoietic function were observed. Table 2Summary of blood routine and coagulation test results of male ( ± SD)IndexesUnitsMale P ControlBone GlueWBC109/L6.5 ± 1.736.44 ± 1.53>0.05NEUT#109/L0.84 ± 0.30.7 ± 0.2>0.05LYMPH#109/L5.22 ± 1.385.29 ± 1.41>0.05MONO#109/L0.39 ± 0.260.4 ± 0.15>0.05EO#109/L0.01 ± 0.010.03 ± 0.01<0.05BASO#109/L0.03 ± 0.020.03 ± 0.02>0.05NEUT%%12.94 ± 3.3511.27 ± 4.06>0.05LYMPH%%80.4 ± 4.2981.66 ± 4.64>0.05MONO%%5.91 ± 3.366.2 ± 1.6>0.05EO%%0.23 ± 0.130.44 ± 0.18<0.05BASO%%0.52 ± 0.230.43 ± 0.24>0.05RBC1012/L9.13 ± 0.488.91 ± 0.27>0.05HGBg/L157.1 ± 9.12155.6 ± 3.41>0.05HCT%48.1 ± 2.8146.81 ± 0.82>0.05PLT109/L1044.1 ± 79.55956 ± 69.76<0.05APTTs17.3 ± 1.317.5 ± 1.3>0.05PTs14.3 ± 0.514.3 ± 0.8>0.05 Summary of blood routine and coagulation test results of male ( ± SD) Table 3Summary of blood biochemical test results of male (± SD)IndexesUnitsMale P ControlBone GlueTBILµmol/L1.8 ± 0.91.8 ± 0.7>0.05TPg/dL7 ± 0.27.1 ± 0.2>0.05ALBg/dL3.7 ± 0.23.7 ± 0.1>0.05GLOBg/dL3.3 ± 0.23.4 ± 0.2>0.05A/G-1.1 ± 0.11.1 ± 0.1>0.05ALTU/L50.1 ± 5.947.2 ± 5.2>0.05ASTU/L153.3 ± 29.1187.7 ± 33.4<0.05ALPU/L129.99 ± 24.4119.4 ± 23.2>0.05BUNmg/dL21 ± 419.8 ± 2.3>0.05CREAµmol/L45.8 ± 3.244.8 ± 4.8>0.05GLUmmol/L7.8 ± 2.16.6 ± 0.7>0.05CGTU/L0.4 ± 0.30.3 ± 0.2>0.05TCmg/dL86.6 ± 23.982.2 ± 1.1>0.05TGmg/dL26.2 ± 12.723.2 ± 6>0.05Kmmol/L4.7 ± 0.34.7 ± 0.3>0.05Nammol/L142.3 ± 1.3143.9 ± 1.8<0.05Clmmol/L96.1 ± 0.894.5 ± 1.7<0.05Cammol/L3.2 ± 0.13.4 ± 0.2<0.05Pmg/dL9.4 ± 0.610.6 ± 1.1<0.05 Summary of blood biochemical test results of male (± SD) Table 4Summary of blood routine and coagulation test results of female ( ± SD)IndexesUnitsMale P ControlBone GlueWBC109/L3 ± 1.053.01 ± 0.58>0.05NEUT#109/L0.56 ± 0.150.42 ± 0.07<0.05LYMPH#109/L2.31 ± 0.892.36 ± 0.68>0.05MONO#109/L0.17 ± 0.080.18 ± 0.08>0.05EO#109/L0.01 ± 0.010.01 ± 0.01>0.05BASO#109/L0.01 ± 0.010.01 ± 0.01>0.05NEUT%%17.22 ± 5.7212.48 ± 3.98<0.05LYMPH%%75.93 ± 7.9980.27 ± 7.19>0.05MONO%%6 ± 2.456.33 ± 3.28>0.05EO%%0.39 ± 0.310.42 ± 0.24>0.05BASO%%0.46 ± 0.250.5 ± 0.28>0.05RBC1012/L8.09 ± 0.657.7 ± 0.49>0.05HGBg/L141 ± 8.5139.4 ± 4.25>0.05HCT%43.14 ± 3.0842.07 ± 1.6>0.05PLT109/L1006.8 ± 143.891015.4 ± 92.88>0.05APTTs18.7 ± 1.618.4 ± 1.2>0.05PTs12.8 ± 0.512.5 ± 0.7>0.05 Summary of blood routine and coagulation test results of female ( ± SD) Table 5Summary of blood biochemical test results of female (±SD)IndexesUnitsMale P ControlBone GlueTBILμmol/L3.1±1.22.8±1.5>0.05TPg/dL8.2±0.38.4±0.4>0.05ALBg/dL4.4±0.24.5±0.3>0.05GLOBg/dL3.8±0.23.9±0.2>0.05A/G-1.2±0.11.1±0.1>0.05ALTU/L64.8±23.456±18.7>0.05ASTU/L154.7±67.7163.2±47.7>0.05ALPU/L69.8±25.158.8±10.8>0.05BUNmg/dL29.6±7.626.8±6.2>0.05CREAμmol/L49.7±752.1±6.9>0.05GLUmmol/L7.8±0.77.3±1.3>0.05CGTU/L0.5 ± 0.50.9 ± 0.5>0.05TCmg/dL116.9 ± 26.6123.7 ± 11.9>0.05TGmg/dL23.9 ± 6.821.7 ± 6>0.05Kmmol/L4.4 ± 0.34.4 ± 0.3>0.05Nammol/L145.4 ± 1.6145.6 ± 1.2>0.05Clmmol/L94.2 ± 1.594.1 ± 1.3>0.05Cammol/L3.3 ± 0.13.5 ± 0.1<0.05Pmg/dL7.4 ± 0.88.5 ± 0.9<0.05 Summary of blood biochemical test results of female (±SD) Changes in weight Body weights of animals were measured weekly throughout the experimental period. Male (Fig. 7A) and female (Fig. 8A) animals in the Bone Glue group exhibited normal body weight gain, with no statistically significant differences in growth rate relative to the control group (P > 0.05). No significant intergroup differences in body weight were noted at any time point, demonstrating that Bone Glue exerted no adverse effect on body weight gain. The body weight and organ weight of male SD rats after Bone Glue implantation. A Body weight changes in male SD rats after 12 weeks of Bone Glue implantation. B Organ weight changes in male SD rats after 12 weeks of Bone Glue implantation. C Changes in organ weight/body weight ratio in male SD rats after 12 weeks of Bone Glue implantation The body weight and organ weight of female SD rats after Bone Glue implantation. A Body weight changes in female SD rats after 12 weeks of Bone Glue implantation. B Organ weight changes in female SD rats after 12 weeks of Bone Glue implantation. C Changes in organ weight/body weight ratio in female SD rats after 12 weeks of Bone Glue implantation. *P<0.05 Organ weight and organ coefficient In males, no statistically significant differences in absolute wet organ weights (Fig. 7B) or organ-to-body weight indices (Fig. 7C) of all organs were observed between the Bone Glue group and the control group (P > 0.05). In females, no significant differences in absolute wet organ weights (Fig. 8B) of all organs were detected between the Bone Glue and control groups (P > 0.05). For organ-to-body weight indices (Fig. 8C), only the brain showed a significant difference (P < 0.05), with no significant changes noted in other organs (P > 0.05). Gross necropsy revealed no Bone Glue-related gross pathological lesions in any group. All organs exhibited normal anatomical localization, with no evidence of hyperemia, edema, atrophy, nodules, ulceration or adhesions. Histopathological examination Histopathological examination of major organs was performed using microscopy, and the results are shown in Fig. 9. Bone Glue ‑treated rats showed intact histological architecture and normal cellular morphology in all examined organs, with no evidence of degeneration, necrosis, inflammatory cell infiltration, hyperplasia, fibrosis or other pathological alterations. No significant intergroup differences in histomorphological findings were observed compared with the control group, and no test article‑related specific histopathological lesions were detected. H&E staining of important organs of SD rats after 12 weeks of Bone Glue implantation Discussion The present study systematically characterized the physicochemical properties and comprehensively evaluated the in vitro and in vivo biocompatibility of a novel injectable and wet‑bonding bone adhesive Bone Glue, which was designed for dental implant fixation and bone defect repair. The key findings demonstrated that this Bone Glue exhibited favorable physicochemical characteristics, including time‑dependent curing behavior, stable titanium adhesion, neutral pH maintenance, and appropriate microporous microstructure, together with excellent in vitro cytocompatibility and favorable in vivo biosafety without subchronic systemic toxicity. These results collectively support the potential of this novel bone adhesive for clinical application. A core requirement for bone adhesives in clinical applications is sufficient and stable bonding strength under wet physiological conditions, especially for titanium‑based dental implants. A study has reported that a bone adhesive can reach a bond strength of about 1.30 MPa within 1 h, and the final wet bond strength to cortical bone can reach about 1.70 MPa [15]. Another study showed that the initial bond strength of an adhesive to bone could reach 0.86 MPa within 15 min [10]. In the current study, the lap‑shear adhesion strength of Bone Glue on titanium substrates in wet condition significantly increased from 0.91 ± 0.14 MPa at initial curing (10 min) to 1.26 ± 0.09 MPa after complete curing (P < 0.05), indicating effective curing progression and enhanced interfacial bonding with prolonged setting time. More importantly, the results demonstrate that the Bone Glue can quickly obtain effective bonding strength in wet condition. The excellent wet adhesion and functionality of Bone Glue rely on the synergistic mechanism of TTCP, bioactive glass, PS, and PGA fibers. TTCP and bioactive glass release calcium ions, which can form strong coordination bonds with PS and PGA respectively [12, 16]. PS and PGA may form ion bridges via calcium ions to significantly improve initial adhesion and shear strength on bone/titanium under wet conditions. Meanwhile, interpenetrating PGA fibers could enhance toughness and reduce collapsibility [11]; after degradation, they create interconnected pores to facilitate osteogenesis and bone ingrowth [17]. FTIR analysis demonstrated that spectral differences between the Bone Glue before and after curing were mainly distributed in the fingerprint region. Strong absorptions at 1000–1500 cm⁻¹ and 1500–1750 cm⁻¹ were assigned to C–O and C = C stretching vibrations, respectively [18]. After curing, both absorptions decreased significantly, with the most obvious attenuation at 1000–1500 cm⁻¹, indicating efficient removal of C–O‑containing hydrophilic groups and structural cross‑linking during the curing process [19]. This structural rearrangement is a critical advantage for wet-bonding: the formation of a compact polymer network not only improves the mechanical strength of the Bone Glue but also enhances its water resistance, which is essential for maintaining adhesive strength in the wet conditions [20]. In contrast to conventional calcium phosphate cements with poor wet cohesion and anti‑washout performance, the cured Bone Glue maintained structural integrity in aqueous environments, which is critical for intraoperative handling and long‑term stability in blood‑rich physiological sites. Maintaining local pH microenvironment stability is a key factor for implantable biomaterials to achieve good biocompatibility, promote tissue integration and prevent secondary infection. The leachate of cured Bone Glue remained within a narrow physiological pH range (7.30–7.35) over 72 h, with only negligible fluctuations. This neutral and stable microenvironment avoids local tissue acidosis, inflammatory reactions, and cytotoxicity induced by acidic degradation products, which are commonly observed in some polymeric adhesive systems [21–23]. In vitro biocompatibility assessment using L‑929 cells revealed that all concentrations of Bone Glue extract supported cell viability above 70%, complying with the ISO 10,993 standard for non‑cytotoxic biomaterials. The cytotoxicity experiment was performed in compliance with ISO 10993-5: 2009 [13] (tests for in vitro cytotoxicity), one of the core parts of the ISO 10,993 series. The grouping method, detection indexes and result evaluation criteria were all implemented as specified in this standard. The standardized experimental system guarantees the credibility of our conclusion that the bone cement is free of cytotoxicity. The non‑cytotoxic nature can be attributed to the biocompatible raw material formulation, including bioactive glass, TTCP, and PS, which eliminate toxic monomers or pro‑inflammatory residues. Unlike PMMA bone cement, which releases cytotoxic monomers and generates intense polymerization exotherm (up to 80–120℃) that causes thermal tissue damage [24, 25], Bone Glue cures mildly under physiological conditions without excessive heat release or hazardous leachate. The 12‑week subchronic systemic toxicity study conducted in Sprague‑Dawley (SD) rats provided robust evidence for in vivo biosafety in accordance with ISO 10,993‑11: 2017 [14] guidelines. No mortality, abnormal clinical signs, or impaired body weight gain were detected in the Bone Glue group throughout the experimental period. Although a few individual hematological and biochemical parameters showed statistically significant differences between the Bone Glue and control groups, all values remained within normal physiological ranges and showed no correlation with material‑related toxic effects [26]. However, this single minor change in the indexes were not accompanied by any abnormal clinical signs, histopathological lesions, or other abnormal indicators. Therefore, this difference is considered to have no obvious biological significance and is not associated with material-related toxicity. No other organs showed significant differences in organ coefficients [27]. Histopathological examination confirmed intact histological structure and normal cellular morphology in all major organs, with no evidence of degeneration, necrosis, inflammatory infiltration, fibrosis, or other pathological lesions associated with Bone Glue implantation. These findings confirm the absence of subchronic systemic toxicity and support the safety of Bone Glue for in vivo applications. Several limitations of this study should be acknowledged. Firstly, this study focused on physicochemical characterization and basic biocompatibility evaluation. Despite the osteogenic activity and degradability of the components (bioactive glass, TTCP, PGAfiber, and PS), their osteogenic activity, degradation and long-term osseointegration efficiency have not been fully studied. Second, the bonding strength to natural bone tissue and dynamic mechanical stability under cyclic loading conditions require further verification. Third, the in vivo animal experiment was limited to a 12-week subchronic toxicity test and organ pathological observation, and the relatively short monitoring period cannot fully reflect the long-term biological effects of the materials. Regarding the long-term evolution of the bone–material interface beyond 12 weeks, based on the confirmed 12-week biosafety and bioactive material composition, the bone adhesive is expected to undergo gradual and mild degradation accompanied by sustained release of calcium, phosphate, and silicate ions [28]. These bioactive ions will induce hydroxyapatite mineralization, facilitate osteoblast infiltration and colonization, and promote new bone ingrowth into the microporous structure of the cured adhesive [20]. With time, progressive material replacement by native bone tissue will occur, leading to stable osseointegration and tight functional integration at the bone–material interface, which is critical for durable clinical performance. Future research will focus on optimizing degradation kinetics to match bone remodeling, incorporating functional modifications (e.g., antibacterial, pro-angiogenic, and drug-loading capabilities), and conducting preclinical evaluations in translational animal models. Conclusions In summary, the novel injectable and wet‑bonding Bone Glue demonstrates favorable physicochemical properties, excellent in vitro cytocompatibility, and no subchronic systemic toxicity in vivo. This biomaterial provides a safe and effective alternative to traditional bone cements and internal fixation devices, holding substantial potential for dental implant fixation and maxillofacial bone defect repair in clinical dental practice. Acknowledgements The authors also thank the cooperative company (Suzhou Jiuxin Medical Technology Co., LTD) for providing the Bone Glue. Abbreviation Polymethylmethacrylate Calcium phosphate bone cement Tetracalcium phosphate Polyglycolic acid Phosphoserine Minimum essential medium Phosphate-buffered saline Fetal bovine serum Methyl thiazolyl tetrazolium Scanning electron microscopy Fourier transform infrared spectroscopy Trihydroxymethylaminomethane White blood cell Neutrophil Lymphocyte Monocytes Basophile Red blood cell Hemoglobin Hematocrit Platelet Prothrombin time Activated partial thromboplastin time Total bilirubin Total protein Albumin Globulin Albumin/globulin Alanine aminotransferase Aspartate aminotransferase Alkaline phosphatase Blood urea nitrogen Creatinine Glucose Glutamyl transpeptidase Total cholesterol Triglyceride Kalium Natrium Chlorine Calcium Phosphorus Hematoxylin-eosin Standard deviations Authors’ contributions Peng Yu designed the method of the study and interpreted the results. Guibin Huang and Bingqing Li conducted the research, collected the data, contributed to analyzing data, and drafted the manuscript. Yining Liu, Xiwen Zhang, Hongzhi Zhou and Jian Wang interpreted the results. All authors read and approved the final manuscript. Funding This research was supported by the Science and Technology Innovation Joint Fund project of Fujian province (grant number 2025Y9743) and the Clinical Medicine Plus X Young Scholars Project of Peking University (grant number PKU2021LCXQ029). Data availability The datasets generated and analyzed during this study are available from the corresponding author upon reasonable request. All essential data supporting the findings are included within the manuscript. Declarations Ethics approval and consent to participate This study was approved by the Animal Ethics Committee of Xiamen Medical College (Approval No.20251023002). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Guibin Huang and Bingqing Li contributed equally to this work. References Associated Data Data Availability Statement The datasets generated and analyzed during this study are available from the corresponding author upon reasonable request. All essential data supporting the findings are included within the manuscript.